<DOC>
<DOCNO>EP-0643718</DOCNO> 
<TEXT>
<INVENTION-TITLE>
IMMUNOSUPPRESSIVE AND TOLEROGENIC MODIFIED LEWIS?C  AND LacNAc COMPOUNDS.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3170	A61K3170	A61K317008	A61K317008	A61K31702	A61K31702	A61K317028	A61K317028	A61P3700	A61P3700	C07H300	C07H306	C07H500	C07H506	C07H508	C07H1100	C07H1100	C07H1500	C07H1504	C07H1510	C07H1512	C07H1514	C07H1518	C07H15203	C07H1900	C07H1910	C07H1920	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	C07H	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61P37	A61P37	C07H3	C07H3	C07H5	C07H5	C07H5	C07H11	C07H11	C07H15	C07H15	C07H15	C07H15	C07H15	C07H15	C07H15	C07H19	C07H19	C07H19	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Disclosed are novel Lewis
<
C
>
 and LacNAc analogues, pharmaceutical compositions containing such analogues, methods for their preparation and methods for their use.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
ALBERTA RES COUNCIL
</APPLICANT-NAME>
<APPLICANT-NAME>
ALBERTA RESEARCH COUNCIL
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
HANNA H RIZK
</INVENTOR-NAME>
<INVENTOR-NAME>
HAQUE WASIMUL
</INVENTOR-NAME>
<INVENTOR-NAME>
IPPOLITO ROBERT M
</INVENTOR-NAME>
<INVENTOR-NAME>
JIANG CONG
</INVENTOR-NAME>
<INVENTOR-NAME>
NIKRAD PANDURANG V
</INVENTOR-NAME>
<INVENTOR-NAME>
SMITH RICHARD H
</INVENTOR-NAME>
<INVENTOR-NAME>
SRIVASTAVA OM P
</INVENTOR-NAME>
<INVENTOR-NAME>
VENOT ANDRE P
</INVENTOR-NAME>
<INVENTOR-NAME>
HANNA, H. RIZK
</INVENTOR-NAME>
<INVENTOR-NAME>
HAQUE, WASIMUL
</INVENTOR-NAME>
<INVENTOR-NAME>
IPPOLITO, ROBERT M.
</INVENTOR-NAME>
<INVENTOR-NAME>
JIANG, CONG
</INVENTOR-NAME>
<INVENTOR-NAME>
NIKRAD, PANDURANG V.
</INVENTOR-NAME>
<INVENTOR-NAME>
SMITH, RICHARD H.
</INVENTOR-NAME>
<INVENTOR-NAME>
SRIVASTAVA, OM P.
</INVENTOR-NAME>
<INVENTOR-NAME>
VENOT, ANDRE P.
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 IMMUNOSUPPRESSIVE AND TOLEROGENIC MODIFIED LEWIS0 AND LacNAc COMPOUNDSBACKGROUND OF THE INVENTION1. Field of the Invention. The present invention is directed toLewisc-YR and LacNAc-YR analogues, pharmaceutical compositions containing such analogues, methods for their preparation and methods for their use.2. References The following references are cited in this application as superscript numbers at the relevant . portion of the application:1 Horowitz, "The Glycoconjugates", Vols. I-V, Pigman, Editor, New York Academic Press (1977, 1978, 1982, 1983).2 Ippolito, et al., U.S. Patent Application Serial No. 07/714,161, filed June 10, 1991 for "Immunosuppresive and Tolerogenic Oligosaccharide Glycosides". 3 Sialic Acids in "Cell Biology Monographs"Schauer, Editor, Vol. 10 (1982).4 Lowe, et al. , Cell, 63:475-485 (1990).5 Phillips, et al. , Science, 250:1130-1132 (1990) . 6 Walz, et al. , Science, 250:1132 et seq.(1990) . 

 Larsen, et al., Cell, 62:467-474 (1990). Ratcliffe, et al., U.S. Patent No. 5,079,353, issued January 7, 1992, for "Sialic Acid Glycosides, Antigens, Immunoadsorbents, and Methods for their Preparation". Ratcliffe, et al., U.S. Patent Application Serial No. 07/278,106, filed November 30, 1988, for "Sialic Acid Glycosides, Antigens, Immunoadsorbents, and Methods for their Preparation".10 Venot, et al., U.S. Patent Application Serial No. 07/771,007, "Methods for the Enzymatic Synthesis of Alpha-sialylated Oligosaccharide Glycosides", filed October 2, 1991. 11 Weinstein, et al., J. Biol. Chem., 257:13845-13853 (1982).12 Reuter, et al., Glycoconjugate J. , .5:133-135 (1988) .13 Ippolito, et al., U.S. Patent Application Serial No. 07/889,017, filed May 26, 1992 for"Immunosuppresive and Tolerogenic Oligosaccharide Glycosides".14 Smith, et al. , Immunology, 5_8:245 (1986).15 Smith, et al., Infection and Immunity, 31: 129 (1980) .16 Hindsgaul, et al., Carbohydr. Res., 109:109- 142 (1982).17 Nicolaou, et al., J. Amer. Chem. Soc, 111:3693-3695 (1990). 18 Ekborg, et al., Carbohydr. Res., 110:55-67(1982) .19 Dahmen, et al., Carbohydr. Res., 118:292-301 (1983) .20 Rana, et al., Carbohydr. Res., 91:149-157 (1981) .21 Amvam-Zollo, et al., Carbohydr. Res., 15fj:199-212 (1986). 

22 Paulsen, et al., Carbohydr. Res., 104: 195-219 (1982) .23 Chernyak, et al., Carbohydr. Res., 128:269- 282 (1984) . 24 Fernandez-Santana, et al., J. Carbohydr. Chem., 8:531-537 (1989).25 Lee et al., Carbohydr. Res., 3_7:193 et seq. (lb. -4). 26 Norberg, et al., Carbohydr. Res., 183:71 et seq. (1988) .27 Petitou, et al.,
</DESCRIPTION>
<CLAIMS>
WHAT IS CLAIMED IS :
1 . A compound of Formula I or II :
where R is selected from the group conεiεting of hydrogen, a saccharide-OR
19
, an oligoεaccharide-OR
19
 having from 2 to 7 oligosaccharide units, or an aglycon having at least 1 carbon atom where R
19
 is hydrogen or an aglycon of at least one carbon atom; Y is selected from the group consisting of oxygen, sulfur, and -NH-;
R
1
 is selected from the group consisting of hydrogen, -NH
2
, -N
3
, -NHS0
3
H, -N 
j
CfOJR^ -N=C(R
5
)
2
, -NHCH(R
5
)
2
, -NHR
6
, -N(R
6
)
2
, -OH, -OR
6
, -S(0)R
6
, -S(0)
2
R
6
 and sulfate, wherein R
4
 is selected from the group consiεting of hydrogen, alkyl of from 1 to 4 carbon atoms; -OR
7
 wherein R
7
 is alkyl of from 1 to 4 carbon atoms, or alkyl of from 2 to 4 carbon atoms substituted with a hydroxyl group, and
-NR
8
R
<
, wherein R
8
 and -^ are independently selected from the group consisting of hydrogen and alkyl of from 1 to 4 carbon atoms, 


 each R
5
 is selected from the group consisting of hydrogen and alkyl of from 1 to 4 carbon atoms, each R
6
 iε alkyl of from 1 to 4 carbon atomε, R
2
 iε selected from the group consisting of hydrogen, -N
3
, -NH
2
, -NHS0
3
H, -NR
n
C(O)R
10
, -N=C(R
11
)
2
, -NHCH(R--)
2
, -NHR
12
, -N(R
12
)
2
, -OH and -OR
12
, wherein R
10
 is selected from the group consiεting of hydrogen, alkyl of from 1 to 4 carbon atomε,
-OR
13
 wherein R
13
 iε alkyl of from 1 to 4 carbon atomε, or alkyl of from 2 to 4 carbon atoms substituted with a hydroxyl group, and
-NR
14
R
15
 wherein R
14
 and R
15
 are independently selected from the group consiεting of hydrogen and alkyl of from 1 to 4 carbon atomε, each R iε selected from the group consisting of hydrogen and alkyl of from 1 to 4 carbon atoms; each R
12
 is alkyl of from 1 to 4 carbon atoms, R
3
 is selected from the group consiεting of hydrogen, fluoro, εulfate and hydroxy;
X- iε selected from the group consiεting of hydrogen, sialyl, sulfate, phosphate, and -CHR
18
C00H where R
18
 iε εelected from the group conεiεting of hydrogen, alkyl of from 1 to 7 carbon atoms and -COOH;
X
2
 is selected from the group conεiεting of hydrogen, sulfate, phosphate, and -CHR
18
COOH where R
18
 is εelected from the group conεisting of hydrogen, alkyl of from 1 to 7 carbon atoms and -COOH; and pharmaceutically acceptable salts thereof; and with the proviso that either at least one of X
1
 or X
2
 iε εulfate, phosphate or -CHR
18
COOH or R
3
 is sulfate. 


 2. A compound of Claim 1 wherein said compound is of Formula I.
3. A compound of Claim 1 wherein said compound is of Formula II.
4. A compound of Claim 1 wherein R_ is selected from the group consisting of hydroxyl, hydrogen or alkoxy of from 1 to 4 carbon atoms.
5. A compound of Claim 1 wherein R
2
 is selected from the group consisting of hydroxyl, alkoxy of from 1 to 4 carbon atoms, -NH
2
, -N
3
 and -NHC(O)R,
0
.
6. A compound of Claim 1 wherein R
3
 is -OH.
7. A compound of Claim 1 wherein X and X
j
 are hydrogen and X
2
 is selected from the group consisting of sulfate, phosphate, and -CHR
18
COOH.
8. A compound of Claim 1 wherein X and X
2
 are hydrogen and X, is selected from the group consisting of sulfate, phosphate, and -CHR
18
COOH.
9. A compound of Claim 2 wherein X, is hydrogen, X
2
 is sulfate, Rj is hydroxyl, R
2
 is selected from the group consisting of -NH
2
 and -NHC(0)CH
3
 and R
3
 is hydroxyl.
10. A compound of Claim 3 wherein X_ is hydrogen, X
2
 is sulfate, R
j
 is hydroxyl, R
2
 is selected from the group consisting of -NH
2
 and -NHC(0)CH
3
 and R
3
 is hydroxyl.
SUBSTITUTE £
>
:2ΞT 


 11. A pharmaceutical composition suitable for administration to a mammal which comprises a pharmaceutically inert carrier and an effective amount of the compound of Claim 1 to modulate a cell-mediated immune response in said mammal.
12. A method for modulating a cell-mediated immune response in a mammal which method comprises administering to said mammal an amount of a compound of Claim 1 effective in modulating said immune reεponse.
13. A method for reducing sensitization of a mammal to an antigen which compriseε administration of an effective amount to the mammal of a compound of Claim 1.
14. A method for reducing sensitization of a mammal to an antigen which
*
 comprises administration of an effective amount to the mammal of a compound of Claim 2.
15. A method for reducing senεitization of a mammal to an antigen which compriεeε administration of an effective amount to the mammal of a compound of Claim 3.
16. A method according to Claim 12 wherein said suppresεion of an immune responεe comprises suppresεion of a DTH reεponεe and induction of tolerance to an antigen.
SUBSTITUTESHEET 

</CLAIMS>
</TEXT>
</DOC>
